Navtemadlin not checked
Kartos Therapeutics, Inc. · KRT-232
FollowEvery change as it happens, and a Monday email
Trials
3 active
12 in total · 4 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth”In the company’s words, NCT05797831 on ClinicalTrials.gov
- Tested for
- Myelofibrosis, Post-PV MF, Post-ET Myelofibrosis, Primary Myelofibrosis, MF, Endometrial Cancer, Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and 1 more
- Main trialPhase 3
- “This clinical trial is evaluating whether addition of navtemadlin to ruxolitinib treatment will provide more clinical benefit than ruxolitinib alone for patients with Myelofibrosis who have a suboptimal response to ruxolitinib treatment alone. Subjects will start by receiving ruxolitinib alone in the run-in period. Those who demostrate a suboptimal response from ruxolitinib alone will then be randomized 2:1 to receive navtemadlin or navtemadlin placebo as add-on treatment to their ongoing ruxolitinib. Randomized means that subjects will be assigned to a group by chance, like a flip of a…”In the company’s words, NCT06479135 on ClinicalTrials.gov
- Other names
- KRT-232
Other drugs for Myelofibrosis
- NavitoclaxAbbVie · Phase 3
- SelinexorKaryopharm Therapeutics Inc · Phase 3
- Ropeginterferon alfa-2bPharmaEssentia · Phase 3
- ElriterceptTakeda · Phase 3
- PelabresibNovartis · Phase 3
- Imetelstat SodiumGeron Corporation · Phase 3
Coming up1
- 31 DecPhase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials12
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 31 Dec 2026 | Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | |
| Phase 2/3Recruiting | Aug 2025 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | |
| Phase 1/2Recruiting | Oct 2022 | Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | |
| Phase 2/3Unknown | 31 Dec 2023 | KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment | |
| Phase 2Terminated | 26 Aug 2022 | KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | |
| Phase 2Unknown | May 2024 | Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis | |
| Phase 1/2Unknown | 11 May 2022 | KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF | |
| Phase 1/2Unknown | Oct 2022 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib | |
| Phase 1/2Terminated | 27 Sep 2023 | An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML) | |
| Phase 1/2Unknown | Nov 2024 | Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma | |
| Phase 1/2Unknown | 31 Dec 2024 | KRT-232 and TKI Study in Chronic Myeloid Leukemia | |
| Phase 1/2Withdrawn | Jun 2025 | Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026